Latest Breaking News On - Liver studies - Page 1 : comparemela.com

Quell Therapeutics Advances QEL-001, Its Multi-Modular Engineered CAR-Treg Cell Therapy, Into Efficacy Cohort Of LIBERATE Phase 1/2 Trial In Liver Tra

Progress in the LIBERATE trial was presented at the American Transplant

United statesUnited kingdomCity ofLuke deveyFrazer hallCorey davisSandi greenwoodLuke henryAmerican transplant congressTherapeutics ltdAmerican transplantQuell therapeutics ltdData safetyMonitoring boardAcademic directorLiver studies

Bluejay Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver (EASL) Congress 2024

Bluejay Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver (EASL) Congress 2024
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

New zealandUnited kingdomCity ofHilario ramosLoghman salimzadehKosh agarwalEdward ganeUniversity health networkUniversity of aucklandInstitute of liverKing college hospitalSchwartz reisman liver research centreTherapeutics announces upcoming presentationsEuropean associationBreaker poster presentationLiver studies

FDA Approves Second Gene Therapy for Hemophilia B

Pfizer reported a list price of $3.5 million for its new gene therapy, Beqvez, for adults with this rare bleeding disorder.

Drug administrationHemophilia haemophiliaBiologic therapyGenomics genomic medicineGene therapyHemophiliab haemophilia bHemophiliaa haemophilia aLiver enzymesLiver studiesUs food and drug administrationNited states food and drug administration

Early Olezarsen Results Show 50% Reduction in Triglycerides

A drug targeting mRNA essential for APO C-III production provided a 50% reduction in triglycerides in BRIDGE-TIMI 73a, the largest ever observed in a controlled trial.

United statesNorth carolinaDaniel sofferBrian bergmarkNehaj pagidipatiNational lipid associationAmerican college of cardiologyDuke clinical research instituteDuke school of medicineAmerican collegeScientific sessionNew englandMajor subgroup failedNorth americaPenn medicineNational lipid

Seladelpar Could Raise the Bar in PBC Treatment

The investigational agent significantly improved liver biomarkers of disease activity and symptoms of pruritus in adults with PBC enrolled in a phase 3 trial.

United statesNew havenGideon hirschfieldDavidn assisToronto centerYale school of medicineDrug administrationLiver diseaseToronto general hospitalMedscape medicalCymabay therapeuticsNew england journalLiver meetingAmerican associationDigestive diseasesYale school